Secukinumab in Giant Cell Arteritis: A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase 2 Trial

Venhoff N, Schmidt W, Bergner R, Rech J, Unger L, Tony HP, Mendelson M, Sieder C, Maricos M, Thiel J (2021)

Publication Type: Conference contribution

Publication year: 2021

Journal

Arthritis and Rheumatology Wiley

Publisher: WILEY

City/Town: HOBOKEN

Pages Range: 4130-4133

Conference Proceedings Title: ARTHRITIS & RHEUMATOLOGY

Authors with CRIS profile

Hans Jürgen Rech Department of Medicine 3 – Rheumatology and Immunology

Involved external institutions

Albert-Ludwigs-Universität Freiburg DE Germany (DE) Immanuel Krankenhaus Berlin DE Germany (DE) Klinikum der Stadt Ludwigshafen am Rhein gGmbH DE Germany (DE) Krankenhaus Dresden-Friedrichstadt, Städtisches Klinikum DE Germany (DE) Novartis AG CH Switzerland (CH)

How to cite

APA:

Venhoff, N., Schmidt, W., Bergner, R., Rech, J., Unger, L., Tony, H.-P.,... Thiel, J. (2021). Secukinumab in Giant Cell Arteritis: A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase 2 Trial. In ARTHRITIS & RHEUMATOLOGY (pp. 4130-4133). HOBOKEN: WILEY.

MLA:

Venhoff, Nils, et al. "Secukinumab in Giant Cell Arteritis: A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase 2 Trial." Proceedings of the ARTHRITIS & RHEUMATOLOGY HOBOKEN: WILEY, 2021. 4130-4133.

BibTeX: Download